Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial

被引：0

作者：

Smith, B. Douglas ^{[1
]}

Cortes, Jorge E. ^{[2
]}

Rea, Delphine ^{[3
]}

Mauro, Michael J. ^{[4
]}

Patwardhan, Pallavi ^{[5
]}

Maegawa, Rodrigo ^{[5
]}

Zacker, Christopher ^{[5
]}

Corbin, Regina ^{[5
]}

Keeping, Sam ^{[6
]}

Sasaki, Koji ^{[7
]}

机构：

[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[3] Hop St Louis, AP HP, Dept Hematol, Paris, France

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] PRECISIONheor, Vancouver, BC, Canada

[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

CML; chronic myeloid leukemia; health care resource use; asciminib; bosutinib; tyrosine kinase inhibitor;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-353

引用

页码：S334 / S334

页数：1

共 31 条

[21] Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION
Breccia, Massimo
Mauro, Michael
Jabbour, Elias
Saglio, Giuseppe
Jimenez-Velasco, Antonio
le Coutre, Philipp
DeGutis, Irene
Khan, Wasiulla
Sy, Oumar
Swanink, Rene
Cortes, Jorge E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S326 - S327
[22] Non-Optimal Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI) in the United States: A Claims Data Analysis
Kota, Vamsi
Wei, David
Yang, Daisy
Romdhani, Hela
Latremouille-Viau, Dominick
Guerin, Annie
Jadhav, Kejal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S365 - S366
[23] An Observational Study of Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY)
Michallet, Mauricette
Cortes, Jorge
Gambacorti-Passerini, Carlo
Hehlmann, Rudiger
Williams, Loretta A.
Goldberg, Stuart L.
Davis, Catherine
De Solda, Francesco
Sen, Ginny P.
Gajavelli, Srikanth
Mauro, Michael J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S229 - S229
[24] ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Atallah, Ehab
Mauro, Michael
Sasaki, Koji
Levy, Moshe
Koller, Paul
Yang, Daisy
Laine, Dramane
Sabo, John
Gu, Ennan
Cortes, Jorge
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S348 - S349
[25] ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI)
Sasaki, Koji
Mauro, Michael J.
Levy, Moshe Y.
Atallah, Ehab L.
Koller, Paul
Maegawa, Rodrigo
Damon, Andrea
Kumar, Julie
Khan, Mahmudul
Cortes, Jorge E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S299 - S299
[26] Relationship Between High Body Mass Index (BMI) and Treatment Outcomes in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Dasatinib or Imatinib: Retrospective Analysis of the Phase 3 DASISION Trial
Breccia, Massimo
Cortes, Jorge E.
Shah, Neil P.
Saglio, Giuseppe
Jimenez-Velasco, Antonio
Le Coutre, Philipp
Brun, Alexander
DeGutis, Irene
Bathena, Sai
Sy, Oumar
Jabbour, Elias
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S230 - S230
[27] Asciminib Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Updated Results From the AIM4CML Study in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
Levy, Moshe
Andorsky, David
Issa, Ghayas
Broun, Edward
Essell, James
Abboud, Camille
Damon, Andrea
Starinsky, Amy
Sadek, Islam
Parveen, Naseema
Mauro, Michael
Deininger, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S367 - S367
[28] Asciminib (ABL001) in Combination with Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Long-Term Frontline Imatinib: A Randomized, Open-Label, Multicenter, Phase 2 Study
Cortes, Jorge E.
Hughes, Timothy P.
Geissler, Jan
Hois, Stephan
Quenet, Sara
Hourcade-Potelleret, Florence
Hertle, Sabine
Saglio, Guiseppe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S222 - S223
[29] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang
Zongru Li
Yazhen Qin
Weiming Li
Na Xu
Bingcheng Liu
Yanli Zhang
Li Meng
Huanling Zhu
Xin Du
Suning Chen
Yang Liang
Yu Hu
Xiaoli Liu
Yongping Song
Lichuang Men
Zi Chen
Qian Niu
Hengbang Wang
Ming Lu
Dajun Yang
Yifan Zhai
Xiaojun Huang
Journal of Hematology & Oncology, 15
[30] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022)
Jiang, Qian
Li, Zongru
Qin, Yazhen
Li, Weiming
Xu, Na
Liu, Bingcheng
Zhang, Yanli
Meng, Li
Zhu, Huanling
Du, Xin
Chen, Suning
Liang, Yang
Hu, Yu
Liu, Xiaoli
Song, Yongping
Men, Lichuang
Chen, Zi
Niu, Qian
Wang, Hengbang
Lu, Ming
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)

← 1 2 3 4 →